As the hepatitis B virus is widely spread and responsible for considerable morbidity and mortality, WHO recommends vaccination from infancy to reduce acute infection and chronic carriers. However, current subunit vaccines are not 100% efficacious and leave 5–10% of recipients unprotected.
Together, we can end viral hepatitis.
We are the only grant-making organization dedicated exclusively to the mission of ending viral hepatitis.
By funding a variety of the most effective activities, EndHep2030 intends to overcome the barriers that prevent countries from properly addressing viral hepatitis — a pandemic that will kill 1.4 million people this year — as a global public health threat.
Our catalytic funding will speed the elimination of viral hepatitis by supporting the development of sustainable strategic plans at the national and sub-national level to guide effective program implementation; by showing how countries can optimize their human and financial resources within health budgets; by increasing the availability of country-specific data that inform where and how to intervene most efficiently and effectively; and, by building health system capacity to deliver quality hepatitis prevention and treatment services.
EndHep2030’s catalytic funding will be the spark that sets this historic effort in motion. MORE
Japanese scientists at the Biomedical Research Institute at the National Institute of Advanced Industrial Science and Technology have created hens that can lay “golden eggs” containing a protein used to treat cancer and hepatitis. These scientists used new genome editing technology to create the hens that can lay multi-million pound golden eggs with high quantities of human interferon beta at a low cost.
HCV is a global and national concern with treatments being easily available for free, or at subsidized rates, across the country and in neighbouring States like Manipur, Meghalaya and Mizoram. However in Nagaland, HCV treatment and testing facilities are still not accessible or available for the general population.
“Setting targets under the National Viral Hepatitis Control Programme, the Indian health ministry had pledged to achieve 100% usage of ingineered safety devices to curtail injection related infections,” said Dr Chandrakant Lahariya, WHO-India.